The first histopathological evidence of trimetazidine for the prevention of contrast-induced nephropathy

References

• Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation. 2002;105(19):2259–2264
   PubMed Web of Science ®Google Scholar
• Murphy SW, Barrett BJ, Parfrey PS. Contrast nephropathy. J Am Soc Nephrol. 2000;11:177–182
   PubMed Web of Science ®Google Scholar
• Gruberg L, Mehran R, Dangas G, et al. Acute renal failure requiring dialysis after percutaneous coronary interventions. Cathet Cardiovasc Intervent. 2001;52:409–416
   PubMed Web of Science ®Google Scholar
• Tumlin J, Stacul F, Adam A, et al.; CIN Consensus Working Panel. Pathophysiology of contrast-induced nephropathy. Am J Cardiol. 2006;98:14K–20K
   PubMed Web of Science ®Google Scholar
• Gami AS, Garovic VD. Contrast nephropathy after coronary angiography. Mayo Clin Proc. 2004;79:211–219
   PubMed Web of Science ®Google Scholar
• Aydoğdu S. Contrast-induced nephropathy. Turk Kardiyol Dern Ars. 2013;41(1):28–30
   PubMedGoogle Scholar
• Elimadi A, Settaf A, Morin D, et al. Trimetazidine counteracts the hepatic injury associated with ischemia-reperfusion by preserving mitochondrial function. J Pharmacol Exp Ther. 1998;286:23–28
   PubMedGoogle Scholar
• Aubert A, Bernard C, Clauser P, Harpey C, Vaudry H. Effect of pnenazine methosulfate on electrophysiological activity of the semisircular canal: antioxidant properties of trimetazidine. Eur J Pharmacol. 1989;174:215–225
   PubMedGoogle Scholar
• Onbasili AO, Yeniceriglu Y, Agaoglu P, et al. Trimetazidine in the prevention of contrast-induced nephropathy after coronary procedures. Heart. 2007;93(6):698–702
   PubMed Web of Science ®Google Scholar
• Singh AP, Junemann A, Muthuraman A, et al. Animal models of acute renal failure. Pharmacol Rep. 2012;64(1):31–44
   PubMed Web of Science ®Google Scholar
• Colbay M, Yuksel S, Uslan I, et al. Novel approach for the prevention of contrast nephropathy. Exp Toxicol Pathol. 2010;62:81–89
   PubMedGoogle Scholar
• Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, Berg KJç. Nephrotoxic effects in high-risk patients undergoing angiography. N Eng J Med. 2003;348(6):491–499
   PubMed Web of Science ®Google Scholar
• Moller E, McIntosh JR, VanSlyke DD. Studies of ureaexcretion. II. Relationshipbetweenurinevolumeandthe rate of ureaexcretionby normal adults. J Clin Invest. 1929;6:427–465
   Google Scholar
• Yoshioka T, Kawada K, Shimada T, Mori M. Lipid peroxidation in maternal and cord blood and protective mechanism against activated-oxygen toxicity in the blood. Am J Obstet Gynecol. 1979;135:372–376
   PubMed Web of Science ®Google Scholar
• Bergmeyer H, Gawehn K, Grasse M. Enzyme as biochemical reagents. In: Bergmeyer HV, ed. Methods of Enzyme Analysis. New York: Academic Press; 1974:438–458
   Google Scholar
• Tietze F. Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Ann Biochem. 1969;27:502–522
   Web of Science ®Google Scholar
• Sun Y, Oberley, LW, Li Y. A simple for clinical assay of superoxide dismutase. Clin Chem. 1988;34:497–500
   PubMed Web of Science ®Google Scholar
• Conover WJ, ed. Some methods based on ranks, section 5.2 several independent samples. In: Practical Nonparametric Statistics 2nd ed., Chapter 5. New York, NY: John Wiley & Sons; 1980: 229–239
   Google Scholar
• Hizoh I, Haller C. Radiocontrast-induced renal tubular cell apoptosis: hypertonic versus oxidative stress. Invest Radiol. 2002;37:428–434
   PubMed Web of Science ®Google Scholar
• Sandhu C, Newman DJ, Morgan R, Belli AM, Oliveira D. The role of oxygen free radicals in contrast induced nephrotoxicity. Acad Radiol. 2002;9(Suppl 2):S436–S437
   PubMedGoogle Scholar
• Yang D, Lin S, Yang D, Wei L, Shang W. Effects of short- and long-term hypercholesterolemia on contrast-induced acute kidney injury. Am J Nephrol. 2012;35(1):80–89
   PubMedGoogle Scholar
• Andrade L, Campos SB, Seguro AC. Hypercholesterolemia aggravates radiocontrast nephrotoxicity: protective role of L-arginine. Kidney Int. 1998;53(6):1736–1742
   PubMed Web of Science ®Google Scholar
• Boyacioglu M, Turgut H, Akgullu C, Eryilmaz U, Kum C, Onbasili OA. The efficient of L-carnitine on oxidative stress responses of experimental contrast-induced nephropathy in rat. J Vet Med Sci. 2013 Aug 20. [Epub ahead of print]
   Google Scholar
• Briguori C, Airoldi F, D’Andrea D, et al. Renal insufficiency following contrast media administration trial (REMEDIAL): a randomized comparison of 3 preventive strategies. Circulation. 2007;115:1211–1217
   PubMed Web of Science ®Google Scholar
• Rahman MM, Haque SS, Rokeya B, Siddique MA, Banerjee SK, Ahsan SA. Trimetazidine in the prevention of contrast induced nephropathy after coronary angiogram. Mymensingh Med J. 2012;21(2):292–299
   PubMedGoogle Scholar
• Harpey C, Clauser P, Labrid C, Freyria JL, Poirier JP. Trimetazidine, a cellular anti-ischemic agent. Cardiovasc Drug Rev. 1989;6:292–312
   Google Scholar
• Stanley WC, Lopaschuck GD, Hall JL, Mccormack JG. Regulation of myocardial carbohydrate metabolism under normal and ischemic conditions: potential for pharmacological interventions. Cardiovasc Res. 1997;33:243–257
   PubMed Web of Science ®Google Scholar
• Maupoil V, Rochette L, Tabard A, Clauser P, Harpey C. Evolution of free radical formation during low-flow ischemia and reperfusion in isolated rat heart. Cardiovasc Drugs Ther. 1990;4:791–795
   PubMed Web of Science ®Google Scholar
• Guarnieri C, Muscari C. Beneficial effects of trimetazidine on mitochondrial function and superoxide production in the cardiac muscle of monocrotaline-treated rats. Biochem Pharmacol. 1988;37:4685–4688
   PubMedGoogle Scholar
• Guarnieri C, Muscari C. Effect of trimetazidine on mitochondrial function and oxidative damage during reperfusion of ischemic hypertrophied myocardium. Pharmacology. 1993;46:324–331
   PubMedGoogle Scholar
• Fabiani JN, Ponzio O, Emerit I, et al. Cardioprotective effect of trimetazidine during coronary artery graft surgery. J Cardiovasc Surg. 1992;33:486–491
   PubMed Web of Science ®Google Scholar
• Ruiz-Meana M. Trimetazidine, oxidative stress, and cell injury during myocardial reperfusion. Rev Esp Cardiol. 2005;58:895–897
   PubMedGoogle Scholar
• Ozden A, Aybek Z, Saydam N, et al. Cytoprotective effect of trimetazidine on 75 min warm renal ischemia-reperfusion injury in rats. Eur Surg Res. 1998;30:227–234
   PubMedGoogle Scholar
• Tsimoyiannis EC, Moutesidou KJ, Moschos CM, Karayianni M, Karkabounas S, Kotoulas OB. Trimetazidine for prevention of hepatic injury induced by ischemia and reperfusion in rats. Eur J Surg. 1993;159:89–93
   PubMedGoogle Scholar